A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-infected Patients with Low CD4+ Counts Under Active Antiretroviral Therapy (SILCAAT)
The purpose of this study is to compare the effects of subcutaneous recombinant interleukin-2 (SC rIL-2) and no SC rIL-2 on disease progression and death over an average follow-up period of 6-7 years period in patients with HIV-1 infection on stable antiretroviral therapy who have a CD4+ cell count between 50 and 299 cells/mm3 and a viral load <10,000 copies/mL.
CHIP is one of four regional trial centers. The Copenhagen Regional Center is responsible for centers in Germany, Spain and Belgium (418 patients have been enrolled from these countries).
For further information please contact the Copenhagen Regional Centre
Investigators website: https://silcaat.ccbr.umn.edu/
The EudraCT number for SILCAAT is 2004-000918-39.
For additional information about or help in using the EudraCT number please contact CHIP.
Updated: 20 Dec 2005